Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM

Northumbria University

Status

Completed

Conditions

Type 1 Diabetes Mellitus

Treatments

Drug: Basal insulin dose

Study type

Interventional

Funder types

Other

Identifiers

NCT02204839

West-Walker3

Details and patient eligibility

About

The investigators hypothesise that reducing basal insulin dose (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk), whilst employing current carbohydrate feeding and rapid-acting insulin dose recommendations will protect patients with type 1 diabetes from early- and late-onset hypoglycaemia following evening time exercise.

Enrollment

10 patients

Sex

Male

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged between 18-50 years old (male or female).
Free from any diabetes related complications (apart from mild background diabetic retinopathy).
HbA1c <8.5%.
Not taking any prescribed medication other than insulin, and treated with a stable insulin regimen composed of a combination of slow/long acting insulin (glargine or detemir) and fast-acting insulin analogues (lispro or aspart), for a minimum of 6 months before the start of the study.
Demonstrate normal cardiac function in response to exercise.

Exclusion criteria

Aged younger than 18, or older than 50 years.
Suffering from, or diagnosed with a diabetes related complication (apart from mild background diabetic retinopathy).
HbA1c >8.5%.
Currently taking prescribed medication, and not currently treated with a stable basal bolus regimen composed of a combination glargine or determir, and lispro or aspart for at least 6 months before the start of the study.
Failure to demonstrate normal cardiopulmonary responses during exercise, or have a medical condition which could prevent completion of exercise or be exacerbated because of.